Clinical Trial Update: Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy [Phase 3]

View source ↗

Summary

This Phase 3 trial compares the capsaicin 179 mg patch to duloxetine for chemotherapy-induced peripheral neuropathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Capsaicin 179 mg patch (capsaicin patch)
• Cymbalta (duloxetine)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Chemotherapy-induced Peripheral Neuropathy | Phase 3 | Status: RECRUITING